Last reviewed · How we verify
Chloroquine chemoprophylaxis alone
At a glance
| Generic name | Chloroquine chemoprophylaxis alone |
|---|---|
| Also known as | CQ |
| Sponsor | Sanaria Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria (PHASE2)
- Comparing Chemoprevention Drugs for School-based Malaria Control (PHASE4)
- Dose Escalation PfSPZ-CVac (PHASE1)
- Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B... (PHASE1)
- Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chloroquine chemoprophylaxis alone CI brief — competitive landscape report
- Chloroquine chemoprophylaxis alone updates RSS · CI watch RSS
- Sanaria Inc. portfolio CI